anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides application of a pseudojujubogenin in preparation of antidepressant medicaments. A structure of the pseudojujubogenin is shown by a formula 1. The inventor of the invention makes series of experiments on influence to independent activities of mouse group samples by the pseudojujubogenin, antidepressant pharmacodynamic screening, antidepressant pharmacodynamic system research, and the like, and results of the experiments show that the pseudojujubogenin within a dosage range has no significant influence to independent activities of mice and has antidepressant effect to activity depression of the mice. The pseudojujubogenin has antidepressant effect to activity depression of animals, and all dosages of the medicaments express functions in fighting against reserpine-induced acinesia symptom of mice. The results of the experiments show that the pseudojujubogenin has certain prevention and treatment effect to depression and can be applied to preparation of antidepressant medicaments. The invention can provide safer and more efficient antidepressant medicaments which have greater clinical application value for human beings.
The photoactive nanofibrous structure with antimicrobial properties of the present invention is intended particularly for filtration of both water and air with catch of microorganisms and in case of air filtration with catch of viruses, too. This nanostructure comprises nanofibers of at least one type of polyurethane modified by at least one photosensitive compound the molecules of which are linked with chains of polyurethane by a covalent bond. The molecules of the photosensitive compound comprise functional groups that are able of reacting with the isocyanate group, especially the groups with acid hydrogen, such as amino-, hydroxy-, or carboxy-groups. A process for preparing the photoactive nanofibrous structure is characterized by preparation of modified polyurethane, whereby in the polyadduct synthesis process covalent bonds are formed by reaction of the isocyanate groups at the ends of the polyurethane chains with acid hydrogen of the functional groups, particularly amino-, hydroxy- or carboxy- groups of the photosensitive compound molecules. These covalent bonds ease the linkage of the molecules of the corresponding photosensitive compound with the polyurethane chains. Subsequently so prepared modified polyurethane is spun from solution in the electrospinning process under the formation of a layer of antimicrobial nanostructure.
Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.
Standardized Mites extract labeled in AU/mL are not interchangeable with non-standardized mite extracts. 

Concentrated extracts must be diluted with sterile diluent prior to first use on a patient for treatment or intradermal testing.

DO NOT INJECT INTRAVENOUSLY. All concentrates of allergenic extracts have the ability to cause serious local and systemic reactions including death in sensitive patients. Sensitive patients may experience severe anaphylactic reactions resulting in respiratory obstruction, shock, coma and /or death. Allergenic extract should be temporarily withheld from patients or the dose of the extract adjusted downward if any of the following conditions exist: (1) Severe symptoms of rhinitis and/or asthma, (2) Infections or flu accompanied by fever and (3) Exposure to excessive amounts of clinically relevant allergen prior to a scheduled injection.
ETHNOPHARMACOLOGICAL RELEVANCE: Suo-Quan-Wan (SQW), a traditional Chinese prescription, has been used for hundreds of years to alleviate overactive bladder (OAB) symptoms such as frequent and nocturnal urination. However, limited modern research on OAB therapeutic targets has hindered the use and development of SQW.
AIM OF THE STUDY: This study aimed to investigate the biological mechanisms and key targets of SQW on OAB in spontaneously hypertensive rats (SHR) using an integrated analysis of network pharmacology, transcriptome and metabolome.
METHODS: Rats were divided into five groups: model group (SHR), control group (WKY), darifenacin group, high dose (SQWH) and low dose (SQWL) group. Urodynamic parameters and histological examination were detected. Network pharmacology, transcriptome, and metabolome were used to screen for disease gene targets, differential mRNA, and differential metabolites, respectively. The biological targets and mechanisms of SQW for OAB were analyzed. Western blotting was performed to verify the proteins of key differential targets.
RESULTS: Urodynamics revealed a significant decrease in storage parameters in SHR. After SQW treatment, the inter-contraction interval, voided volume and bladder capacity increased by 2-3 times, as well as bladder compliance. Additionally, SQW improved the pathological changes in the urinary tract epithelium and the detrusor layer of the bladder in SHR. Metabolomic results showed an increase in arachidonic acid (AA) and cyclic adenosine monophosphate (cAMP) in plasma, suggesting the involvement of arachidonic acid metabolism and purine metabolism in SQW treatment. The downregulation of cytochrome P450 1B1 (CYP1B1), thromboxane-A synthase (TBXAS1), polyunsaturated fatty acid 5-lipoxygenase (ALOX5), and cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B) were confirmed through topological analysis and Venn analysis of omics data and network pharmacology. These proteins affected the metabolism of AA and cAMP, respectively, and consequently affected downstream proteins, such as transient receptor potential (TRP) cation channel proteins (e.g. TRPV1, TRPA1, and TRPM8), myosin light chain kinase (MLCK), and the phosphorylation of myosin regulatory light chain (p-MLC).
CONCLUSION: This study initially elucidated the importance of AA and cAMP in the treatment of SQW, indicating the AA-CYP1B1/TBXAS1/ALOX5-TRPA1/TRPV1/TRPM8 and cAMP-PDE4B-MLCK-p-MLC pathways as the important pathways in SQW-treated SHR bladder in vivo.
All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.
Each tablet for oral administration contains lithium carbonate USP, 300 mg and the following inactive ingredients: calcium stearate, microcrystalline cellulose, povidone, purified water, sodium lauryl sulfate, and sodium starch glycolate. 

Each capsule for oral administration contains lithium carbonate USP, 150 mg, 300 mg or 600 mg and the following inactive ingredient: talc. The capsule shells contain black monogramming ink, FD&C Red No. 40 (300 mg and 600 mg only), gelatin and titanium dioxide. The black monogramming ink contains ammonium hydroxide, ethanol, iron oxide black, isopropyl alcohol, N-butyl alcohol, propylene glycol and shellac glaze.

Each 5 mL of solution for oral administration contains lithium ion (Li+), 8 mEq (equivalent to amount of lithium in 300 mg of lithium carbonate), alcohol 0.3% v/v and the following other inactive ingredients: citric acid, purified water, raspberry blend, sodium benzoate and sorbitol solution.

Lithium Oral Solution is a palatable oral dosage form of lithium ion. It is prepared in solution from lithium hydroxide and citric acid in a ratio approximately di-lithium citrate.

Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer.

The empirical formula for Lithium Citrate is C6H5Li3O7; molecular weight 209.93. Lithium acts as an antimanic.

Lithium Carbonate, USP is a granular, white powder with molecular formula Li2CO3 and molecular weight 73.89.
The invention relates to a vitroceramic element having a continuous glass phase and a crystal phase consisting of tetragonal leucite. Said vitroceramic element comprises a glass phase that is resistant to cracking and a crystal phase which consists of leucite crystals and is distributed in a substantially homogeneous manner in the glass phase. The crystal phase is provided with a grain size distribution of about 5 percent to about 70 percent of a first group of leucite crystals having grain sizes of < 1 µm and about 30 percent to about 95 percent of a second group of leucite crystals having grain sizes of = 1 µm. Preferably, the Li2O ratio in the glass ceramic element amounts to less than 0.5 percent by weight. Preferably, both the glass phase and the crystal phase have essentially no cracks. The corresponding glass ceramic elements are particularly suitable for use in the dental field, especially as facing ceramics.
OBJECTIVE: We aimed to evaluate the effect of hyperbilirubinemia and phototherapy on total apoptotic, platelet-derived, endothelial-derived, and tissue factor (TF)-positive apoptotic microparticle (MP) levels in neonates with nonhemolytic pathologic hyperbilirubinemia.
METHODS: Thirty-three term neonates with nonhemolytic pathologic hyperbilirubinemia and 25 healthy term neonates were included. MP levels were analyzed by flow cytometry using peripheral blood samples only once for the neonates in the control group and twice for the neonates in the study group (before and after phototherapy). Annexin V-positive MPs were defined as apoptotic MPs. Platelet-derived MPs were defined as those containing CD31. MPs containing CD144 were defined as endothelial-derived MPs, and MPs expressing TF were identified as those containing CD142.
RESULTS: The rates of total apoptotic and endothelial-derived apoptotic MPs were significantly higher in the study group than the control group before phototherapy (P = 0.012 and P = 0.003, respectively) and after phototherapy (P = 0.046 and P = 0.001, respectively). Total apoptotic, platelet-derived, endothelial-derived, and TF-positive apoptotic MPs did not show any significant differences before and after phototherapy in the study group (P = 0.908, P = 0.823, P = 0.748, and P = 0.437, respectively).
CONCLUSIONS: Our study demonstrated that total apoptotic and endothelial-derived apoptotic MPs are increased in cases of nonhemolytic pathologic hyperbilirubinemia. We showed that phototherapy does not have a significant effect on apoptotic MP levels. Further studies are needed to evaluate the risk of elevated apoptotic MPs on the development of thromboembolism in neonates with nonhemolytic pathologic hyperbilirubinemia.
Disclosed herein are methods to treat cognition disorders, particularly those associated with aging. The method comprises administering a combination of a carnitine and an oxidant. Preferably the oxidant is thioctic acid. Preferably 0.12 grams to 3 grams of carnitine (particularly ALC) and 0.12 and 1.5 grams of R-α-lipoic acid are administered. Optionally, coenzyme Q and/or creatine also are administered. Preferably 10 mg to 500 mg/day of coenzyme Q10 and 1 to 30 grams/day of creatine are administered. The same method can be used to treat cognition deficits associated with carbon monoxide poisoning, mild traumatic brain injury, Type 2 diabetes mellitus, obsessive-compulsive disorder, environmental toxin exposure, and other conditions.
A device for preparing a radioactive water solution to be infused in a patient includes a reaction chamber ( 13 ) in which radioactive water vapour is formed by the catalysed reaction of oxygen gas containing oxygen-15 and hydrogen gas. A diffusion chamber ( 14 ) is provided which allows the radioactive water to penetrate, but which prevents the penetration of gasses. Tubes ( 26 ) and valves ( 16, 18 ) direct a sterile saline solution to the diffusion chamber ( 14 ), and then direct the saline solution containing radioactive water out from the diffusion chamber to a patient, or to a decay coil ( 22 ) being a part of the device. A measuring instrument is provided for measuring the radioactivity of the radioactive solution. The device is characterized in that the diffusion chamber ( 14 ), the tubes ( 26 ) the valves ( 16, 18 ), the radioactivity measuring instrument ( 17 ), and preferably also the reaction chamber  913 ), are mounted in the same frame  50 , whereby they form a separate unit i.e. a water module ( 30 ), which as one entity can be detached from the lead shield ( 10 ) surrounding the device.
All participants enrolled from CDEB025A2211 (n=162) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
All nurses were recruited from 3 tertiary hospitals in central China from 3rd October, 2019 to 15th December, 2019. A total of 992 clinical nurses from different nursing departments were recruited through convenience sampling. Data were collected using General information questionnaire, the Professional Quality of Life Scale, the Connor-Davidson Resilience Scale and General Perceived Self-Efficacy Scale.
Unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. Localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. The most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. This occurs most commonly in patients following prolonged self-medication, which is contraindicated. If rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. To minimize the possibility of a serious allergic reaction, Cetacaine Topical Anesthetic Gel should not be applied for prolonged periods except under continual supervision. Dehydration of the epithelium or an escharotic effect may also result from prolonged contact.
A topical formulation for application to exposed body tissue, comprises a silver oxide and zinc oxide, intimately dispersed within a carrier medium, where the silver oxide includes a silver (II) oxide. The ratio of zinc oxide to silver (II) oxide may be at least 1:1. At least 0.05% by weight of the formulation may be the silver oxide, and at least 0.05% may be zinc oxide. Preferably, the carrier medium is beeswax, and the formulation may further include jojoba oil. The formulation may have an antimicrobial effect. The zinc oxide acts to whiten the formulation, and promotes less staining of clothes.
Retrospective: 2 doses of JE vaccines. 2 doses of JEV-L respectively administered at 8 months of age and 2 years old.
The present invention discloses a method for preparing post-menopause urine gonadotropin with high purification. The present invention is characterized in that a proper quantity of urofollitropin with high purification and a proper quantity of human uroxanthin auxin with high purification are respectively weighed according to the proportion of required urofollitropin and human uroxanthin auxin and are firstly dissolved in an appropriate buffer solution or water without heat source, dissolution is carried out by the buffer solution, and a pH value is from 4.0 to 10.0; the solution contains alkali metal ions such as kalium ions, sodium ions, etc. or contains ammonium radical ions, and can also be a dilute acid solution such as phosphoric acid, diluted hydrochloric acid, or acetic acid, etc.; after being precipitated in organic solvent, the obtained solution is in vacuum drying or is directly in freeze drying; a drying method comprises the following steps that the protein in a precipitation solution of the organic solvent of propanone, ethanol, etc. is in vacuum drying so that a dry substance is obtained, or the protein can be directly in freeze drying or is concentrated and desalted by a method of ultrafiltration, etc. and is in freeze drying then; therefore, the post-menopause urine gonadotropin with high purification is obtained.
OBJECTIVE: The aim of this study was to comprehensively investigate the potential relationship between blood volatile organic compounds (VOCs) and overactive bladder (OAB) risk.
METHODS: A total of 11,183 participants from the 2007-2020 National Health and Nutrition Examination Survey (NHANES) were included in this cross-sectional study. We used multivariate logistic regression models to investigate the relationship between nine blood VOCs and OAB risk. Restricted cubic spline (RCS) analysis was used to investigate the dose-response relationship between blood VOCs and OAB. In addition, the overall association of blood VOCs with OAB risk was assessed by weighted quantile sum (WQS) regression model. Finally, we conducted subgroup analyses to explore the findings in different high-risk populations.
RESULTS: After adjusting for potential confounders, logistic regression analysis revealed that blood 2,5-dimethylfuran (aOR = 2.940, 95% CI: 1.096-7.890, P = 0.032), benzene (aOR = 1.460, 95% CI: 1.044-2.043, P = 0.027) and furan (aOR = 9.426, 95% CI: 1.421-62.500, P = 0.020) were positively independent associated with the risk of OAB. And dose-response risk curves indicated that 2,5-dimethylfuran, benzene and furan in the blood were linearly positive associated with OAB risk. WQS regression analysis showed that exposure to mixed blood VOCs increased the risk of OAB (OR = 1.29, 95% CI: 1.11-1.49), with furans having the greatest weight. In subgroup analyses, we found that OAB was more susceptible to blood VOCs in young and middle-aged, male, non-hypertensive, and alcohol-drinking populations.
CONCLUSIONS: The results of this study indicate that high exposure to VOCs is independently and positively associated with OAB risk in U.S. adults, particularly 2,5-dimethylfuran, benzene, and furan. In addition, age, gender, hypertension and alcohol consumption may influence the association. Our study provided novel epidemiologic evidence to explore the potential role of environmental pollutants in OAB.
We propose to complete a randomized controlled trial (RCT) of 201 subjects with medication treated diabetes and evidence of poor adherence to a statin medication (\<70% medication possession ratio (MPR) determined through pharmacy records; no combination meds). Study subjects will use GlowCaps to store their statin medication.

Arm 1 will receive weekly feedback containing general information about the subject's adherence (i.e., reminding the subject how many days that week he or she took the medication). Arm 2 will be provided the same weekly feedback and the information of whether his or her adherence is above or below the average adherence in their arm, along with a message of encouragement tailored to their place in the arm distribution. Subjects with perfect adherence will receive: "You took your pill every day for the last 7 days. Great job! Keep it up" with their weekly adherence report. Subjects with less than perfect adherence and adherence rate in the top 50% of the arm will receive: "You took your pill for \*\* days out of the last 7 days. Your medication adherence was as good or better than half of people in this study. Taking your pill every day would improve your health even more" with their weekly adherence report. Subjects with less than perfect adherence and adherence rate in the bottom 50% of the arm will receive: "You took your pill for \*\* days out of the last 7 days. Your medication adherence was in the bottom half of the people in this study. If you took your pill more often, you could be in the top half of people in the study" with their weekly adherence report. Adherence records will be displayed on each subject's Way to Health (WTH) account in all arms. Arm 3 will be the usual care control.
BACKGROUND: In otosurgical training, cadaveric temporal bones are primarily used to provide a realistic tactile experience. However, using cadaveric temporal bones is challenging due to their limited availability, high cost, and potential for infection. Utilizing current three-dimensional (3D) technologies could overcome the limitations associated with cadaveric bones. This study focused on how a 3D-printed middle ear model can be used in otosurgical training.
METHODS: A cadaveric temporal bone was imaged using microcomputed tomography (micro-CT) to generate a 3D model of the middle ear. The final model was printed from transparent photopolymers using a laser-based 3D printer (vat photopolymerization), yielding a 3D-printed phantom of the external ear canal and middle ear. The feasibility of this phantom for otosurgical training was evaluated through an ossiculoplasty simulation involving ten otosurgeons and ten otolaryngology-head and neck surgery (ORL-HNS) residents. The participants were tasked with drilling, scooping, and placing a 3D-printed partial ossicular replacement prosthesis (PORP). Following the simulation, a questionnaire was used to collect the participants' opinions and feedback.
RESULTS: A transparent photopolymer was deemed suitable for both the middle ear phantom and PORP. The printing procedure was precise, and the anatomical landmarks were recognizable. Based on the evaluations, the phantom had realistic maneuverability, although the haptic feedback during drilling and scooping received some criticism from ORL-HNS residents. Both otosurgeons and ORL-HNS residents were optimistic about the application of these 3D-printed models as training tools.
CONCLUSIONS: The 3D-printed middle ear phantom and PORP used in this study can be used for low-threshold training in the future. The integration of 3D-printed models in conventional otosurgical training holds significant promise.
The management of allergic bronchopulmonary aspergillosis (ABPA) includes two important aspects namely institution of immunosuppressive therapy in the form of glucocorticoids to control the immunologic activity, and close monitoring for detection of relapses. Another possible target is to use antifungal agents to attenuate the fungal burden secondary to the fungal colonization in the airways. Oral corticosteroids are currently the treatment of choice for ABPA associated with bronchial asthma. They not only suppress the immune hyperfunction but are also anti-inflammatory.

Itraconazole, an oral triazole with relatively low toxicity, is active against Aspergillus spp. in vitro and in vivo. The activity of itraconazole against Aspergillus spp. is more than that of ketoconazole. The administration of itraconazole can eliminate Aspergillus in the airways and can theoretically reduce the allergic responses in ABPA. We hypothesize that itraconazole when given in the acute stages of ABPA will decrease the chances of relapse and progression to glucocorticoid-dependent ABPA.